Skip to main content
    I

    iBio, Inc. Common Stock (IBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.78
    +0.00 (+0.26%)

    Market Cap: $50.21M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(10/21)
    Avg Surprise
    -11.66%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.07
    Range$-0.10 - $-0.05
    6 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.08+3.2%
    60d ago$-0.08+3.2%
    30d ago$-0.08+6.3%
    7d ago$-0.070.0%
    Current$-0.07
    Revenue Consensus
    $16670
    Range$0 - $100000
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.08
    Range$-0.12 - $-0.06
    6 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.07-11.1%
    60d ago$-0.07-11.1%
    30d ago$-0.09+3.1%
    7d ago$-0.080.0%
    Current$-0.08
    Revenue Consensus
    $0
    Range$0 - $0
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.08---
    Sep 26EST
    		-$-0.07---
    Jun 26
    Reported Aug 28
    		$-0.04$-0.07+42.86%Beat+87.5%
    Mar 26
    Reported May 12
    		$-0.06$-0.06-2.05%Miss+86.8%
    Dec 25
    Reported Feb 10
    		$-0.09$-0.06-50.00%Miss+81.3%
    Sep 25
    Reported Nov 12
    		$-0.29$-0.43+32.56%Beat+37.0%
    Jun 25
    Reported Sep 5
    		$-0.32$-0.36+11.11%Beat+64.5%
    Mar 25
    Reported May 2
    		$-0.49$-0.32-53.13%Miss+42.6%
    Dec 24
    Reported Feb 10
    		$-0.48$-0.46-4.35%Miss+89.2%
    Sep 24
    Reported Nov 12
    		$-0.46$-0.46+0.00%Beat-91.9%
    Jun 24
    Reported Sep 25
    		$-0.90$-0.47-91.89%Miss+49.9%
    Mar 24
    Reported May 13
    		$-0.85N/AN/ABeat+92.2%
    Dec 23
    Reported Feb 9
    		$-4.42$0.00N/ABeat+79.5%
    Sep 23
    Reported Nov 14
    		$-0.24$0.00N/ABeat+99.8%
    Jun 23
    Reported Sep 27
    		$-1.80N/A+78.05%Beat+8.2%
    Mar 23
    Reported May 11
    		$-11.00$-7.20-52.78%Miss+63.3%
    Dec 22
    Reported Feb 14
    		$-21.60$-12.50-72.80%Miss+13.6%
    Sep 22
    Reported Oct 11
    		$-112.60$-35.00-221.71%Miss-11160.0%
    Jun 22
    Reported Sep 27
    		$-1.96$-2.12+7.55%Beat-19700.0%
    Mar 22
    Reported May 12
    		$-30.00$-27.50-9.09%Miss-50.0%
    Dec 21
    Reported Feb 14
    		$-25.00$-20.00-25.00%Miss-25.0%
    Sep 21
    Reported Nov 15
    		$-1.00$-1.25+20.00%Beat+90.0%
    Jun 21
    Reported Sep 27
    		$0.01N/A+100.05%Beat+116.7%
    Mar 21
    Reported May 17
    		$-20.00$-20.00+0.00%Beat-2798.6%
    Dec 20
    Reported Feb 16
    		$-20.00$-17.50-14.29%Miss-9423.8%
    Sep 20
    Reported Oct 13
    		$-10.00N/A+60.00%Beat-4247.8%
    Mar 20
    Reported May 15
    		$-0.06N/AN/ABeat+72.7%
    Dec 19
    Reported Feb 14
    		$-0.69N/AN/ABeat-187.5%
    Sep 19
    Reported Nov 14
    		$-0.21N/AN/ABeat+16.0%
    Jun 19
    Reported Aug 26
    		$-0.23N/AN/ABeat+39.5%
    Mar 19
    Reported May 10
    		$-0.22N/AN/ABeat+37.1%
    Dec 18
    Reported Feb 13
    		$-0.24N/AN/ABeat+41.5%
    Sep 18
    Reported Nov 13
    		$-0.25N/AN/ABeat+40.5%
    Jun 18
    Reported Sep 18
    		$-0.38N/AN/ABeat+22.4%
    Mar 18
    Reported May 11
    		$-0.35N/AN/ABeat+20.5%
    Dec 17
    Reported Feb 14
    		$-0.41N/AN/ABeat-13.1%
    Sep 17
    Reported Nov 9
    		$-0.42N/AN/ABeat-
    Jun 17
    Reported Sep 15
    		$-0.49N/AN/ABeat-
    Mar 17
    Reported May 15
    		$-0.44N/AN/ABeat-
    Dec 16
    Reported Feb 21
    		$-0.36N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.62EV/EBITDAN/A
    Price/FCF-3.42xFCF Yield-29.21%
    Profitability
    Profit Margin0.00%Operating Margin-30138.00%
    ROE-65.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-663.04x
    Current Ratio7.85xQuick Ratio7.85x
    Trading Statistics
    Beta1.26Avg Volume881.53K
    52-Week High$3.8252-Week Low$0.73

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.93
    SMA 20$1.07
    SMA 50$1.24
    SMA 200$1.77
    EMA 10$0.91
    EMA 20$1.02
    EMA 50$1.20
    EMA 200$1.49

    MACD

    Line: -0.13Signal: -0.10Hist: -0.03

    ADX

    ADX: 33.1+DI: 9.0-DI: 35.8

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down96.0
    PSAR$1.00

    Bollinger Bands

    Upper Band$1.43
    Lower Band$0.72
    %B Position6573%(Upper)
    Band Width0.09

    RSI (14-Day)

    Oversold
    20.1

    Momentum Oscillators

    Stoch %K7.4
    Stoch %D6.8
    Williams %R-89.7
    ROC (10d)-29.5%
    Momentum-0.33
    CCI (20d)-136.9
    MFI (14d)20.5

    Volatility Measures

    ATR (14d)$0.08(10.8%)
    StdDev (20d)0.18
    Hist Vol72.2%(High)

    Volume Flow

    VWAP$0.78
    OBV323.8M
    AD Line-261.7M
    CMF (20d)-0.235

    Volume Metrics

    Avg Vol (20d)844.8K
    Vol Ratio0.4x(Low)
    VWMA (20d)$1.04

    Pivot Points

    R3$0.89
    R2$0.85
    R1$0.82
    Pivot Point$0.77
    S1$0.74
    S2$0.70
    S3$0.66

    Advanced Oscillators

    TSI-50.14
    Ultimate Osc31.0
    KST-258.87

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$100,000$200,000$0$200,000$0$175,000$0$0$50,000
    Cost of RevenueN/A$0$0$0N/A$0$0$0$281,000$0$0$0
    Gross ProfitN/A$0$0$100,000$200,000$0$200,000$0$175,000$0$0$50,000
    Operating Expenses$11.38M$8.37M$9.45M$6.05M$5.40M$4.88M$4.62M$4.11M$3.58M$3.63M$4.50M$5.15M
    R&D$8.56M$3.25M$4.28M$3.55M$3.22M$1.91M$1.88M$1.30M$1.14M$904,000$1.53M$1.61M
    SG&A$-2,182,000$5.11M$5.17M$2.50M$2.17M$2.97M$2.74M$2.80M$2.44M$2.72M$2.96M$3.55M
    Operating Income$-11,380,000$-8,365,000$-9,445,000$-5,951,000$-5,198,000$-4,879,000$-4,419,000$-4,106,000$-3,409,000$-3,626,000$-4,496,000$-5,103,000
    Interest Income$733,000$657,000$493,000$267,000$79,000$72,000$112,000$174,000$223,000$43,000$42,000$55,000
    Interest Expense$-46,000$22,000$41,000$36,000$44,000$54,000$57,000$57,000$60,000$52,000$34,000$26,000
    Income Before Tax$-10,601,000$-7,730,000$-8,993,000$-5,720,000$-5,163,000$-4,861,000$-4,364,000$-3,989,000$-3,246,000$-2,635,000$-4,488,000$-5,074,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-10,601,000$-7,730,000$-8,993,000$-5,720,000$-5,163,000$-4,861,000$-4,364,000$-3,989,000$-7,778,000$-3,172,000$-8,211,000$-5,746,000
    EBITDA$-11,165,000$-7,930,000$-9,378,000$-5,832,000$-4,913,000$-4,290,000$-4,445,000$-3,828,000$-3,128,000$-2,294,000$-4,147,000$-4,695,000
    EBIT$-11,380,000$-8,365,000$-9,445,000$-5,951,000$-5,198,000$-4,879,000$-4,419,000$-4,106,000$-3,409,000$-2,626,000$-4,496,000$-5,103,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IBIO

    News

    Form 4 Ibio Inc: Alexandra Kropotova (Director) For: 14 October By Investing.com

    This article reports on a Form 4 filing for Ibio Inc, indicating that Director Alexandra Kropotova had activity related to the company on October 14th. The filing was published on October 16...

    Investing.com Nigeria•10/15/26•Neutral

    Form 4 Ibio Inc: Antonio Bernardino Guimaraes Parada (Director) For: 14 October

    This article reports a Form 4 filing for Ibio Inc, indicating an insider transaction by Director Antonio Bernardino Guimaraes Parada on October 14. The brief notice from Investing.com includes the stock symbol IBIO...

    Investing.com India•10/15/26•Neutral

    38,000 options granted to iBio (IBIO) director Alexandra Kropotova vest monthly over 12 months.

    iBio, Inc. director Alexandra Kropotova was granted 38,000 stock options on October 14, 2026, with an exercise price of $0.7800 per share. These options will vest pro rata in monthly installments over twelve months...

    Stock Titan•10/15/26•Neutral

    At $0.78 per share, 38,000 options go to iBio (IBIO) director Elizabeth Stoner.

    iBio (IBIO) director Elizabeth Stoner was granted 38,000 stock options on October 14, 2026. These options have an exercise price of $0.78 per share and are set to expire on October 13...

    Stock Titan•10/15/26•Neutral

    A director receives 38,000 iBio (IBIO) stock options with a $0.78 exercise price.

    iBio director David Arkowitz was granted 38,000 stock options on October 14, 2026, with an exercise price of $0.78 per share. These options will vest pro rata in monthly installments over 12 months...

    Stock Titan•10/15/26•Neutral

    IBIO Valuation and Fair Value

    P/E
    -1.6x
    P/FCF
    -3.4x
    PEG
    0.0x
    P/B
    1.0x
    See GNG's fair value

    IBIO Profitability: Margins, ROIC and FCF

    Operating margin
    -30138.0%
    Net margin
    0.0%
    ROE
    -65.7%
    FCF margin
    -23796.0%
    FCF yield
    -29.2%

    IBIO Competitors

    CompanyTicker
    Myomo IncMYO
    Tela Bio IncTELA
    Alterity Therapeutics LtdATHE
    Mereo BioPharma Group PLC ADRMREO
    Mink Therapeutics IncINKT
    Envoy Medical Inc.COCH
    Inspira Technologies Oxy BHN LtdIINN
    Klotho Neurosciences, Inc.KLTO

    Sector: Healthcare

    IBIO Analyst Ratings

    Consensus
    Buy
    Analysts
    9
    Strong Buy
    1
    Buy
    8
    Hold
    0
    Sell
    0
    Strong Sell
    0

    IBIO Bull Case vs Bear Case

    Bull case

    • 100.0% of IBIO's analyst ratings are Buy or Strong Buy.

    Bear case

    • IBIO beat EPS estimates in 37.5% of its last 8 reported quarters.
    • IBIO's quarterly revenue changed -100.0% year over year.

    IBIO Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -2.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.07
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About IBIO

    Does IBIO pay dividends?

    iBio, Inc. Common Stock (IBIO) does not currently pay a regular dividend.

    What is IBIO's market cap?

    iBio, Inc. Common Stock (IBIO) has a market capitalization of $50.21M with a current stock price of $0.78.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In